Loading...
Market
Where will BridgeBio's infigratinib be approved by September 30, 2025?
2
Resolution / Starting Odds
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other regions • 25%
Not approved in any region • 25%
Regulatory announcements from FDA, EMA, and other relevant authorities
Story
BridgeBio's Infigratinib Receives FDA Breakthrough Therapy Designation, Stock Surges 64.2%
Sep 17, 2024, 11:32 AM
BridgeBio Pharma announced that its investigational therapeutic, infigratinib, has been awarded Breakthrough Therapy Designation by the FDA. This marks the first time such a designation has been given to a treatment for achondroplasia. The designation is expected to expedite the development and review of infigratinib, which is being developed as an oral treatment for children with achondroplasia. Following this announcement, BridgeBio's stock ($BBIO) surged by 64.2%.
View original story
Similar markets
Yes • 50%
No • 50%
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%